Android app on Google Play

Neurocrine (NBIX) Shares Plunge as Data on NBI-98854 Fails to Hit Primary Endpoint

March 26, 2012 4:08 PM EDT Send to a Friend
Neurocrine Biosciences (Nasdaq: NBIX) shares have fallen more than 11 percent after data from a Phase II study of VMAT2 inhibitor NBI-98854 for tardive dyskinesia did not meet the primary endpoint.

The stock last traded at $7.88. Shares closed at $8.99.




You May Also Be Interested In


Related Categories

Momentum Movers

Add Your Comment